To determine the safety and efficacy of azithromycin in the treatment of lung infection with M.avium complex and M. abscessus lung disease.
To study the safety and efficacy of azithromycin in combination treatment for M. abscessus and MAC lung disease
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
66
Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
The University of Texas Health Science Center at Tyler
Tyler, Texas, United States
Clinical and microbiological outcomes such as clinical symptoms and laboratory cultures
neg cultures X3( sputum conversion)
Time frame: 6 months
Microbiological cultures
culture neg 1 yr on treatment
Time frame: 1yr
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.